Acurx Pharmaceuticals, Inc. (ACXP) Stock Analysis & Investment Frameworks

Acurx Pharmaceuticals, Inc. (ACXP) stock analysis on Invetso. Review Acurx Pharmaceuticals, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.

Acurx Pharmaceuticals, Inc. Company Overview

Acurx Pharmaceuticals, Inc. Key Financial Metrics

About Acurx Pharmaceuticals, Inc.

Acurx Pharmaceuticals, Inc. functions as a clinical-stage biopharmaceutical firm focused on developing innovative antibiotic treatments for bacterial infections. The company's primary drug candidate is ibezapolstat, an antibiotic that utilizes a novel mechanism of action by targeting the polymerase IIIC enzyme. Ibezapolstat has successfully completed Phase II clinical trials for addressing Clostridium difficile infections. Additionally, Acurx is progressing with ACX-375C, an investigational therapeutic suitable for both oral and injectable administration. This compound is being developed to combat various gram-positive bacteria, including resistant strains such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and penicillin-resistant Streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was established in 2017 and is headquartered in Staten Island, New York.

Acurx Pharmaceuticals, Inc. Investment Frameworks

Invetso analyzes Acurx Pharmaceuticals, Inc. (ACXP) across the following frameworks:

Explore More ACXP Research